Medicine by the Numbers

A Collaboration of TheNNT.com and AFP

Buprenorphine Maintenance vs. Placebo for Opioid Dependence

 

Am Fam Physician. 2017 Mar 1;95(5):online.

image

 Enlarge     Print

BUPRENORPHINE MAINTENANCE VS. PLACEBO FOR OPIOID DEPENDENCE

BenefitsHarms

1 in 4 using low-dose buprenorphine (2 to 6 mg) had retention in treatment

No study-related medication mortality was reported

1 in 3 using medium-dose buprenorphine (7 to 16 mg) had retention in treatment

Uncertain adverse effects

1 in 2 using high-dose buprenorphine (≥ 16 mg) had retention in treatment

BUPRENORPHINE MAINTENANCE VS. PLACEBO FOR OPIOID DEPENDENCE

BenefitsHarms

1 in 4 using low-dose buprenorphine (2 to 6 mg) had retention in treatment

No study-related medication mortality was reported

1 in 3 using medium-dose buprenorphine (7 to 16 mg) had retention in treatment

Uncertain adverse effects

1 in 2 using high-dose buprenorphine (≥ 16 mg) had retention in treatment

Details for This Review

Study Population: Adults with opioid dependence

Efficacy End Points: Treatment retention and illicit drug use suppression

Harm End Points: Mortality and adverse effects

Narrative: The United States is facing an opioid epidemic. Since 1999, overdose deaths involving opioids and heroin have quadrupled.1 Methadone, a full agonist, has traditionally been used to treat opioid and heroin dependence. Buprenorphine, a partial agonist, is an appealing alternative because it causes lower physical dependence, milder withdrawal symptoms, and is less likely to cause an overdose.2 This review examines the effectiveness of buprenorphine vs. placebo for retention in treatment and illicit opioid use, as measured by positive urinalysis or self-reported use.

This Cochrane review included 31 studies with 5,430 participants, the majority of whom were male with an average age of 30 years.2 High-quality evidence shows that buprenorphine at all doses is more effective than placebo in retaining patients in treatment. An analysis of five studies using low-dose buprenorphine (2 to 6 mg) in 1,131 participants showed a benefit in treatment retention over placebo (relative risk [RR] = 1.5; 95% confidence interval [CI], 1.19 to 1.88). Medium-dose buprenorphine (7 to 16 mg) had slightly better patient retention in treatment (RR = 1.74; 95% CI, 1.06 to 2.87). High-dose buprenorphine (≥ 16 mg) was the most effective at retaining study participants in treatment (RR = 1.82; 95% CI, 1.15 to 2.90).

This review found moderate-quality evidence that buprenorphine is effective in suppressing illicit drug use, but only at doses of 16 mg or greater (three studies; 729 participants; standardized mean deviation [SMD] = −1.17; 95% CI, −1.85 to −0.49; number needed to treat = 2). Low-dose and medium-dose buprenorphine did not suppress illicit opioid use (SMD = 0.10; 95% CI, −0.80 to 1.01 and SMD = −0.08; 95% CI, −0.78 to 0.62, respectively).

Only five studies reported mortality data; no deaths were reported in three of the studies. In two of the studies there was a 20% mortality rate reported in the control group. Two deaths unconnected to the study medication were reported in one trial due to stab wounds and cancer.

Caveats: All trials included were randomized, controlled studies with low risk of bias. Twenty-two were double-blinded and 10 were open comparative trials. Of note, four of the studies used a 1-mg dose of buprenorphine as the placebo. The authors note that this is unlikely to bias results given the clinically insignificant dose. The included studies varied in their reporting of adverse events, if they reported them at all.

Current treatment of opioid dependence generally uses an individualized dosing schedule; therefore, flexible-dose methadone or flexible-dose buprenorphine may be more clinically relevant. This review also compared 11 studies with 1,391 participants receiving either flexible-dose methadone or flexible-dose buprenorphine. The methadone group was more likely to be retained in treatment (RR = 0.83; 95% CI, 0.73 to 0.95). There was no difference between the two groups with regard to illicit opioid use (SMD = −0.11; 95% CI, −0.23 to 0.02).

Conclusion: Based on current evidence, buprenorphine is effective in retaining patients in treatment at all doses; however, only doses of at least 16 mg prevent illicit drug use during therapy. Studies using flexible-dose buprenorphine without using buprenorphine as a placebo may be more clinically relevant to actual practice. The harms from treatment are currently unclear because of poor reporting of adverse events.

The views expressed are those of the author and do not reflect the official policy or position of the Bayne-Jones Army Community Hospital, the Army Medical Department, the Department of Defense, or the U.S. government.

This series is coordinated by Dean A. Seehusen, MD, MPH, AFP Contributing Editor, and Daniel Runde, MD, from the NNT Group.

A collection of Medicine by the Numbers published in AFP is available at https://www.aafp.org/afp/mbtn.

Author disclosure: No relevant financial affiliations.

REFERENCES

1. CDC National Vital Statistics System. The opioid epidemic: by the numbers. http://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf. Accessed June 1, 2016.

2. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207.

 

 

Copyright © 2017 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Apr 15, 2018

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article